Abstract:BackgroundIschemic stroke (IS) is the most common and life-threatening arterial manifestation of antiphospholipid syndrome (APS). It is related to high mortality and severe permanent disability in survivors. Thus, it is essential to identify patients with APS at high risk of IS and adopt individual-level preventive measures. This study was conducted to identify risk factors for IS in patients with APS and to develop a nomogram specifically for IS prediction in these patients by combining the adjusted Global Anti-Phospholipid Syndrome Score (aGAPSS) with additional clinical and laboratory data.MethodsA total of 478 consecutive patients with APS were enrolled retrospectively. All patients were randomly assigned to the training and validation cohorts. Univariate and multivariate binary logistic analyses were conducted to identify predictors of IS in the training cohort. Then, a nomogram was developed based on these predictors. The predictive performance of the nomogram for the training and validation cohorts was evaluated by determining areas under the receiver operating characteristic curve (AUROC) and creating calibration plots. A decision curve analysis (DCA) was conducted to compare the potential net benefits of the nomogram with those of the aGAPSS.ResultsDuring a mean follow-up period of 2.7 years, 26.9% (129/478) of the patients were diagnosed with IS. Binary logistic regression analysis revealed that five risk factors were independent clinical predictors of IS: age (P < 0.001), diabetes (P = 0.030), hyperuricemia (P < 0.001), the platelet count (P = 0.001), and the aGAPSS (P = 0.001). These predictors were incorporated into the nomogram, named the aGAPSS-IS. The nomogram showed satisfactory performance in the training [AUROC = 0.853 (95% CI, 0.802–0.896] and validation [AUROC = 0.793 (95% CI, 0.737–0.843)] cohorts. Calibration curves showed good concordance between observed and nomogram-predicted probability in the training and validation cohorts. The DCA confirmed that the aGAPSS-IS provided more net benefits than the aGAPSS in both cohorts.ConclusionAge, diabetes, hyperuricemia, the platelet count, and the aGAPSS were risk factors for IS in patients with APS. The aGAPSS-IS may be a good tool for IS risk stratification for patients with APS based on routinely available data.

Thrombin-driven Neural Net Diagnoses the Antiphospholipid Syndrome without the Need for Interruption of Anticoagulation

Monitoring of anticoagulation in thrombotic antiphospholipid syndrome

Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies

Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies

Thrombin Generation Assay in Antiphospholipid Antibodies Positive Subjects as a Personalized Thrombotic Risk Assessment: State of the Art and Perspectives

A-161 Diagnosis of Lupus Anticoagulant Cases using Deep Neural Networks

A Novel Agapss-Based Nomogram for the Prediction of Ischemic Stroke in Patients with Antiphospholipid Syndrome.

Abstract TP104: Functional Prognostication of Patients Receiving Thrombolytics in Acute Ischemic Stroke With Machine Learning

Taipan snake venom time has high sensitivity for lupus anticoagulants in non‐anticoagulated, triple positive antiphospholipid syndrome patients

Clinical Performance of Antibodies to Prothrombin and Thrombin in Chinese Patients with Antiphospholipid Syndrome: Potential Interest in Discriminating Patients with Thrombotic Events and Non-Thrombotic Events

Screening for lupus anticoagulants in patients treated with vitamin K antagonists

Biological markers of high risk of thrombotic recurrence in patients with antiphospholipid syndrome: A literature review

Coagulation parameters predict COVID-19-related thrombosis in a neural network with a positive predictive value of 98

Challenges of laboratory testing in patients suspected of antiphospholipid syndrome: practical implications for clinicians

Evaluation of an integrated activated partial thromboplastin time (Cephen LS/Cephen) for the detection of lupus anticoagulant

Design and validation of algorithms to identify venous thromboembolism in the French National Healthcare Database

Clinical and Laboratory Diagnosis of Antiphospholipid Syndrome: A Review

Non-criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: Diagnostic Value Added

“Non-Criteria” Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort

Validation of three prediction models for thrombosis recurrence in antiphospholipid syndrome patients based on a prospective cohort

Targeting thromboinflammation in antiphospholipid syndrome